MPPT - Passive immunotherapy for the treatment of wounds and wounds associated with dermatological conditions
Why chose MPPT
Demonstrated therapeutic effect
Removes antibiotic resistant infections
Only natural ingredients
No known side-effects
No known allergic reactions
What is MPPT?
MPPT is a white odourless powder to be applied directly to the surface of wounds and ulcers that cannot be sutured or where the sutured wound has sprung open.
MPPT is used where normally antibiotics or antiseptics would have been used, e.g. gentamicin, iodine (cadexomer, povidone), silver (Ag), PHMB (polihexidine), octenidine, honey, Manuka honey, chlorhexidine and DACC (Sorbact).
MPPT removes the bacterial and fungal inhibition of the immune system. This returns control of the wound and the wound environment to the immune system which can now efficiently combat the infection and promote healing.
MPPT is the only product on the market that in itself has been approved as a "treatment for wounds".
All other technologies used in the treatment of wounds have been approved as "tools or aids to be used in wound care", e.g. for the absorption of wound exudate and it is then assumed that this will have a positive impact on the wound healing process. The permission to claim MPPT to be a treatment with a therapeutic effect separates it from dressings, creames etc. and places it in a category comparable to pharmaceuticals. This permission was given based on the strong clinical data package and safety profile.
MPPT support the necessary processes to prepare the wound bed for healing
♦ Autolytic debridement.
♦ Infection removal - without the use of antibiotics and antiseptics.
♦ Infiltration removal – i.e. clears the affected deeper tissue in the entire wound region.
These processes lead to faster tissue regeneration - granulation and epithelialisation.
These processes are necessary for wound healing and closure.
MPPT can be used for
♦ Closure of wounds that cannot be sutured
♦ Preparing an area for surgery by removing soft-tissue infection in the area
♦ Removing reminants of a diffuse tissue infection and supporting wound healing following surgery.
♦ Preventing infection in a surgical wound
♦ Inflammatory conditions with disruption of epithelial barriers in the skin
What Acapsil does
External facing regions of our body work in synergy with the microbes of the environment to protect our body. On the skin, and hence in wound healing, this means that the ever changing skin-microbiome (the ecosystem of bacteria, fungi, viruses and mites) is necessary and must be conserved and nurtured in the best possible way. If the government of the microbiome is taken over by a specific strain of microbes, i.e. if the balance of the microbiome is disturbed, an infection arises. An infection on the skin or in a wound is removed by restoring the balance between the thousands of different inhabitants of the microbiome so that they all thrive without dominating. Only the immune system knows what the right balance is on that particular spot of skin/wound. Consequently, the immune system must be allowed to govern the microbiome and maintain the balance.
Bacteria and fungi use toxins and enzymes as weaponry against other microbes and the immune system to gain control. As protective armour against the immune system the bacteria and fungi hide inside a biofilm that acts as a shield or fortress that cannot be penetrated by the immune cells (or by antibiotics).
Acapsil removes the damaging toxins and enzymes whereby the immune cells regain their strength and abilities; and
Acapsil disrupts the shielding biofilm. This allows the newly strengthened immune cells to enter the biofilm and selectively remove unwanted or excess microbes. This restores the balance of the microbiome which again will promote healing.
Therefore, Acapsil works by returning the power over the healing process to the individual’s immune system – this makes Acapsil a passive immunotherapy.
Antimicrobial resistance / AMR
♦ Acapsil will remove antibiotic-resistant infections.
♦ Acapsil will not contribute to the creation of new resistance.
Acapsil is temperature sensitive and needs to be stored refrigerated.
Acapsil was compared to antibiotic and antiseptic. Acapsil reduced time for removing infection and starting healing by 60% and number of hospitalisation days by 31% relative to these two major product groups. These effects were seen for general wounds, diabetic foot ulcers and venous leg ulcers.
10 patients with dehisced surgical wounds. All wounds proceeded towards healing after 3 to 5 days with Acapsil and all closed. Standard of care would have been 1 week with UrgoClean plus 2 weeks with TNP (pump) to reach a similar stage where the wound could proceed towards healing – assuming no complications.
University Hospital Birmingham, UK, evaluated MPPT in three patients with chronic inactive stable PG ulcers.
Acapsil has been able to initiate the healing of several non-healing wounds and ulcers, which had not responded to a wide range of approaches.
This in vivo study had the same outcome as the clinical study.
Bilyayeva O, Neshta VV, Golub A, Sams-Dodd F. (2017) Comparative Clinical Study of the Wound Healing Effects of a Novel Micropore Particle Technology: Effects on Wounds, Venous Leg Ulcers, and Diabetic Foot Ulcers. Wounds Epub 2017 May 25.
Clinical case reports on file.
”It’s not too much of an exaggeration to say Acapsil changed my life. From 4 weeks of absolute hell, in pain 24 hours a day, struggling at work and looking at possibly taking time off – to being pain-free, getting a full night’s sleep and back to normal at work.” NH